Altimmune, Inc. (ALT1.MX)
Mexico · MXN · Healthcare · Biotechnology
MX$42.25 (+0.00%) as of
Key statistics
- Market cap
- 8.22B
- EPS (TTM)
- -13.68
- Dividend yield
- 0.00%
- 52-week range
- 0.00 – 102.00
- Beta
- 0.06
- Revenue (TTM)
- 31k
- Profit margin
- 0.00%
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Gaithersburg, MD, United States
- Employees
- 57
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.